Preparation and evaluation of cyclosporine A-containing proliposomes: A comparison of the supercritical antisolvent process with the conventional film method

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 5079-5091

  Karn, Pankaj Ranjan ^a   Jin, Su Eon ^a   Lee, Benjamin Joon ^a   Sun, Bo Kyung ^a   Kim, Min Soo ^b   Sung, Jong Hyuk ^a   Hwang, Sung Joo ^a  

^a Yonsei University   (South Korea)

^b Pusan National University   (South Korea)

Author keywords

Cyclosporin A; Proliposomes; Restasis ; Supercritical antisolvent process; Thin film method

Indexed keywords

CYCLOSPORIN A; LIPOSOME; PROLIPOSOME; UNCLASSIFIED DRUG; CYCLOSPORIN; LACTOSE;

ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; FILM; INTERMETHOD COMPARISON; LIGHT SCATTERING; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLYDISPERSITY INDEX; SCANNING ELECTRON MICROSCOPY; SUPERCRITICAL ANTISOLVENT PROCESS; SUPERCRITICAL FLUID; X RAY DIFFRACTION; ZETA POTENTIAL; CHEMISTRY; HEAT; NANOTECHNOLOGY;

CYCLOSPORINE; DRUG STABILITY; HOT TEMPERATURE; LACTOSE; LIPOSOMES; NANOTECHNOLOGY; PARTICLE SIZE;

EID: 84908542052     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S70340     Document Type: Article

References (37)

1. Gupta C, Chauhan A. Ophthalmic delivery of cyclosporine A by punctual plugs. J Control Release. 2011;150(1):70-76.
2. Karn PR, Cho W, Park HJ, Park JS, Hwang SJ. Characterization and stability studies of a novel liposomal cyclosporin A prepared using the supercritical fluid method: comparison with the modified conventional Bangham method. Int J Nanomedicine. 2013;8:365-377.
3. Malaekeh-Nikouei B, Jaafari MR, Tabassi SAS, Samiei A. The enhancement of immunosuppressive effects of cyclosporine A on human T-cells using fusogenic liposomes. Colloids Surf B Biointerfaces. 2008;67(2):238-244.
4. Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003;56(3):307-318.
5. Utine CA, Stern M, Akpek EK. Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm. 2010;18(5):352-361.
6. Karn PR, Kim HD, Kang H, Sun BK, Jin SE, Hwang SJ. Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: comparative study with the conventional cyclosporin A emulsion. Int J Nanomedicine. 2014;9(1): 3791-3800.
7. Guan P, Lu Y, Qi J, et al. Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int J Nanomedicine. 2011;6: 965-974.
8. Ranjita S. Nanosuspensions: a new approach for organ and cellular targeting in infectious diseases. J Pharm Invest. 2013;43(1):1-26.
9. Klyashchitsky BA, Owen AJ. Drug delivery systems for cyclosporine: achievements and complications. J Drug Target. 1998;5(6):443-458.
10. Beauchesne PR, Chung NS, Wasan KM. Cyclosporine A: a review of current oral and intravenous delivery systems. Drug Dev Ind Pharm. 2007;33(3):211-220.
11. Payne NI, Timmins P, Ambrose CV, Ward MD, Ridgway F. Proliposomes: a novel solution to an old problem. J Pharm Sci. 1986;75(4): 325-329.
12. Payne NI, Browning I, Hynes CA. Characterization of proliposomes. J Pharm Sci. 1986;75(4):330-333.
13. Karn PR, Cho W, Hwang SJ. Liposomal drug products and recent advances in the synthesis of supercritical fluid-mediated liposomes. Nanomedicine (Lond). 2013;8(9):1529-1548.
14. Hiremath PS, Soppimath KS, Betageri GV. Proliposomes of exemestane for improved oral delivery: formulation and in vitroevaluation using PAMPA, Caco-2 and rat intestine. Int J Pharm. 2009; 380(1-2):96-104.
15. Xia F, Hu D, Jin H, Zhao Y, Liang J. Preparation of lutein proliposomes by supercritical anti-solvent technique. Food Hydrocoll. 2012;26(2): 456-463.
16. Pasquali I, Bettini R, Giordano F. Supercritical fluid technologies: an innovative approach for manipulating the solid-state of pharmaceuticals. Adv Drug Deliv Rev. 2008;60(3):399-410.
17. Xia F, Jin H, Zhao Y, Guo X. Supercritical antisolvent-based technology for preparation of vitamin D3 proliposome and its characteristics. Chin J Chem Eng. 2011;19(6):1039-1046.
18. Hwang S-J, Park H-J, Cho W, et al, inventors; Foundation of University-Industry Research Collaboration of Chungnam National University, assignee. New methods and apparatus for preparing liposomes. Korean patent KR2011-00969622011. 2011 Aug 31.
19. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13(1): 238-252.
20. Shah NM, Parikh J, Namdeo A, Subramanian N, Bhowmick S. Preparation, characterization and in vivo studies of proliposomes containing Cyclosporine A. J Nanosci Nanotechnol. 2006;6(9-10): 2967-2973.
21. Song K-H, Chung S-J, Shim C-K. Preparation and evaluation of proliposomes containing salmon calcitonin. J Control Release. 2002; 84(1-2):27-37.
22. Lai J, Lu Y, Yin Z, Hu F, Wu W. Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. Int J Nanomedicine. 2010;5:13-23.
23. Paulsson M, Edsman K. Controlled drug release from gels using surfactant aggregates: I. Effect of lipophilic interactions for a series of uncharged substances. J Pharm Sci. 2001;90(9):1216-1225.
24. Otake K, Imura T, Sakai H, Abe M. Development of a new preparation method of liposomes using supercritical carbon dioxide. Langmuir. 2001;17(13):3898-3901.
25. Otake K, Shimomura T, Goto T, et al. Preparation of liposomes using an improved supercritical reverse phase evaporation method. Langmuir. 2006;22(6):2543-2550.
26. Kadimi US, Balasubramanian DR, Ganni UR, Balaraman M, Govindarajulu V. In vitro studies on liposomal amphotericin B obtained by supercritical carbon dioxide-mediated process. Nanomedicine. 2007; 3(4):273-280.
27. Naik S, Patel D, Surti N, Misra A. Preparation of PEGylated liposomes of docetaxel using supercritical fluid technology. J Supercrit Fluids. 2010;54(1):110-119.
28. Epstein-Barash H, Orbey G, Polat BE, et al. A microcomposite hydrogel for repeated on-demand ultrasound-triggered drug delivery. Biomaterials. 2010;31(19):5208-5217.
29. el Tayar N, Mark AE, Vallat P, Brunne RM, Testa B, van Gunsteren WF. Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations. J Med Chem. 1993;36(24):3757-3764.
30. Al-Angary A, Bayomi M, Khidr S, Al-Meshal M, Al-Dardiri M. Characterization, stability and in vivo targeting of liposomal formulations containing cyclosporin. Int J Pharm. 1995;114(2):221-225.
31. Al-Meshal MA, Khidr SH, Bayomi MA, Al-Angary AA. Oral administration of liposomes containing cyclosporin: a pharmacokinetic study. Int J Pharm. 1998;168(2):163-168.
32. Guo J, Ping Q, Chen Y. Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and Sandimmun Neoral. Int J Pharm. 2001;216(1-2):17-21.
33. Demetzos C. Differential Scanning Calorimetry (DSC): a tool to study the thermal behavior of lipid bilayers and liposomal stability. J Liposome Res. 2008;18(3):159-173.
34. Xu H, He L, Nie S, et al. Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. J Control Release. 2009;140(1):61-68.
35. Dubes A, Parrot-Lopez H, Abdelwahed W, et al. Scanning electron microscopy and atomic force microscopy imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins. Eur J Pharm Biopharm. 2003;55(3):279-282.
36. Aksungur P, Demirbilek M, Denkbaş EB, Vandervoort J, Ludwig A, Unlü N. Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies. J Control Release. 2011;151(3):286-294.
37. Bothun GD, Knutson BL, Strobel HJ, Nokes SE. Liposome fluidization and melting point depression by pressurized CO2 determined by fluorescence anisotropy. Langmuir. 2005;21(2):530-536.